Propanc Biopharma plans Phase 1b first-in-human PRP trial in Australia in 2026

• Propanc Biopharma on May 20, 2026 outlined plans to start a first-in-human Phase 1b study of its PRP drug candidate in 30-40 advanced solid-tumor patients later this year, with results to be presented in the future.
• The trial is designed to assess safety and tolerability for a higher-dose, once-weekly intravenous formulation, marking a shift from earlier compassionate-use dosing.
• Prior compassionate-use findings were already published, with patients exceeding expected survival and no severe side effects reported.
• The company expects Phase 1b to support subsequent Phase 2 studies in pancreatic cancer and ovarian cancer to test whether PRP can show clinical benefit in those settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.